Clinical pharmacology of AMG 181, a gut‐specific human anti‐α4β7 monoclonal antibody, for treating inflammatory bowel diseases
British Journal of Clinical Pharmacology2014Vol. 78(6), pp. 1315–1333
Citations Over TimeTop 10% of 2014 papers
Wei‐Jian Pan, Kathleen Köck, William A. Rees, Barbara Sullivan, Christine M. Evangelista, Mark Yen, Jane M. Andrews, Graham Radford‐Smith, Peter J. Prince, Kaz Reynhardt, David R. Doherty, Sonal Patel, Christine D. Krill, Kefei Zhou, Jing Shen, Lynn Smith, Jason M. Gow, Jonathan Lee, Anthony M. Treacy, Zhigang Yu, Virginia M. Platt, Dominic Borie
Abstract
AMG 181 has PK/PD, safety, and effect profiles suitable for further testing in subjects with inflammatory bowel diseases.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study(1999)81 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- Determination of plasma P-selection in patients with ulcerative colitis and their clinical significance(2004)